Skip To Main Content
Synat Keam on Muck Rack

Synat Keam

As seen in: The BMJ, Texas Medical Center, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Synat

Contact Synat, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

474 Mechanistic insights on immune checkpoint inhibitor-induced recurrent inflammatory arthritis

|
By Synat Keam, Yuanteng Jeff Li, Yanshuo Chu, Jean Tayar
| The BMJ Verified
Regular and Young Investigator Award Abstracts Checkpoint Blockade Therapy 474 Mechanistic insights on immune checkpoint inhibitor-induced recurrent inflammatory arthritis Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Open in Who Shared View Duplicates (154) Issue with article?

Toxicity in the Era of Immune Checkpoint Inhibitor Therapy

|
By Synat Keam, Naimah Turner, Fernanda G. Kugeratski, Rene Rico
| Texas Medical Center
Abstract Immune checkpoint inhibitors (ICIs) reinvigorate anti-tumor immune responses by disrupting co-inhibitory immune checkpoint molecules such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4). Although ICIs have had unprecedented success and have become the standard of care for many cancers, they are often accompanied by off-target inflammation that can occur in any organ system.
Open in Who Shared Issue with article?

“Immune checkpoint inhibitor therapy for malignant pleural mesothelioma”

|
By Wee Loong Chin, Alistair DB Cook, Synat Keam
| Lung Cancer Verified
Highlights • Checkpoint inhibitors in mesothelioma. • Advances in predictive biomarker identification in mesothelioma. • Biomarker discovery and treatment options in mesothelioma. • Data science in mesothelioma. Abstract Mesothelioma is a rare and universally fatal cancer linked to exposure to asbestos. Until recently, standard of care treatment was chemotherapy; a treatment resulting in a minimal survival extension, and not improved upon for almost twenty years.
Open in Who Shared Issue with article?
See all 3 articles